Human immunodeficiency virus-1-derived lentiviral vectors have been increasingly used for gene delivery in both preclinical and clinical models. Numerous studies have shown that dendritic cells (DC) transduced with concentrated lentiviral vectors can induce primary T-cell responses to viral and tumor antigens. In this study, we attempted to generate influenza hemagglutinin-specific CD4 T cells using lentiviral vectors containing the signal sequence and human lysosome-associated membrane protein to target hemagglutinin to the major histocompatibility complex class II processing pathway. Autologous dendritic cells were generated in serum-free medium and transduced with concentrated, high-titer lentiviruses to stimulate autologous T cells. Unexpectedly, we failed to generate influenza hemagglutinin-specific CD4 T cells rather than T cells specific for fetal calf serum (FCS). By limiting dilution, we established several FCS-specific CD4 T-cell clones restricted by human leukocyte antigen-DR1 and human leukocyte antigen-DR4. Lentiviruses produced in human serum-adapted 293 cells or in serum-free medium were unable to sensitize dendritic cells for recognition by FCS-specific CD4 T-cell clones. Our results indicate that residual FCS in concentrated lentiviral pellets is, in part, responsible for its immunogenicity. These FCS-specific CD4 T cells may be useful in testing clinical grade lentiviral vectors for the presence of contaminating FCS.
Introduction
Human immunodeficiency virus-1 (HIV-1)-derived lentiviral vectors (LVs) are being used with increasing frequency for gene delivery in vitro and in vivo; [1] [2] [3] [4] recently, the first clinical trial to use lentiviral vectors was reported. 4 The effectiveness of LVs is based on their ability to infect both dividing and non-dividing cells and to integrate into the host cell genome, allowing for prolonged target gene expression. 5, 6 Additionally, there is minimal immunogenicity associated with LVs, especially compared with adenoviral or herpes virus-based vectors. 7, 8 A variety of steps have been taken to decrease the risk and minimize the immunogenicity of LVs by (1) eliminating the accessory genes (vif, vpr, vpu and nef), which are not essential for transduction of the packaging construct, 9 (2) minimizing the chances of generating replication-competent viruses through recombination by development of a three-plasmid expression system that contains packaging, envelope and vector plasmids 10 and (3) the construction of self-inactivating vectors by deleting the majority of the U3 region in the 3 0 LTR, so that viral RNA cannot be produced in target cells. 11 Lentiviral-based gene therapy has been widely assessed in both pre-clinical and clinical models, indicating that there is little concern about the LV itself inducing an immune response. [1] [2] [3] [4] [5] [6] [8] [9] [10] [11] [12] Dendritic cells (DC) are promising targets for immunotherapy because of their specialized ability to present antigens to both CD4 and CD8 T cells thereby inducing primary as well as secondary immune responses. There is a compelling evidence supporting transduction of DC with concentrated LVs that have been prepared in 293T cells cultured with fetal calf serum (FCS). The transduced DC can then be used for priming antigen-specific T cells to HIV, influenza and melanoma antigens. [13] [14] [15] [16] [17] [18] [19] We hypothesized that antigen-specific CD4 T cells could be generated using DC lentivirally transduced with an antigen-specific gene as antigen-presenting cells. It has been shown that the lysosomal-associated membrane protein (LAMP-1) can target an antigen into the major histocompatibility complex (MHC) class II processing pathway resulting in enhanced presentation to CD4 + T cells in vitro and in vivo. 20 To test our hypothesis, we constructed an LV containing a signal sequence, LAMP-1 cDNA and influenza hemagglutinin (HA) antigen. This s-HA-LAMP-1 LV was prepared at high titer and was used to transduce DC from human leukocyte antigen (HLA)-DR4 + healthy blood donors. In an attempt to generate HA-specific CD4 T cells, the DC were then incubated with autologous CD4 T cells. Surprisingly, we failed to produce influenza HA-specific CD4 T cells; instead, the CD4 T cells that we generated were directed against FCS. Our results have important implications in the use of LVs for human gene therapy and emphasize that it is important to minimize foreign proteins, such as FCS, in the production of LVs.
Results

Functional analysis of lentiviral hemagglutinin vectors
To optimize the generation of HA-specific CD4 T cells, three lentiviral vectors were constructed. The first contained HA alone (LV-HA), the second also encoded LAMP-1 (LV-s-HA-LAMP-1) and the third expressed nerve growth factor receptor (LV-HA-NGFR) in addition to HA. The HA lentiviral transduced cells and the lentiviral constructs, LV-HA, LV-s-HA-LAMP-1 and LV-HA-NGFR (Figure 1 , data not shown for LV-HA-NGFR), were verified for their function by GM-CSF release assays using HA-specific CD4 + T-cell clones. Figure 2 shows that HA-specific CD4 T-cell clone 3 (HA-3) can recognize Epstein-Barr virus (EBV)-transformed B cells (Priess, HLA-DR4 + ) pulsed with HA peptide (HA306-318), Priess transduced with LV-HA and LV-s-HA-LAMP-1, but not Priess transduced with LV-green fluorescent protein (GFP) or untreated Priess. These results show that the lentiviral HA-transduced cells, the lentiviral LV-HA, LV-s-HA-LAMP-1 and LV-HA-NGFR constructs are functional.
Transduction efficiency of DC
Dendritic cells were generated from the peripheral blood monocytes and cultured in the presence of interleukin (IL)-4 and GM-CSF under strictly autologous conditions and serum-free medium. Day 5 immature DC were transduced with LV-GFP or LV-HA (multiplicity of infection (MOI) ¼ 1-50) overnight, and mature cocktails were added on day 6. On day 8 DC showed high levels of CD80, CD83, CD86 and HLA-DR expression (data not shown). Transduction efficiency of LV-GFP and LV-HA in DC was 50-90%, and 10-30%, respectively (data not shown). We chose an MOI of 25-50 to transduce DC in our subsequent experiments. 
Characterization of the immunogenic components
These unexpected findings, in contrast with the published results showing that lentivirally transduced DC can stimulate primary antigen-specific T cells in vitro, [13] [14] [15] [16] [17] [18] [19] prompted us to identify the antigens recognized by bulk CD4 T cells. By limiting the dilution we established several CD4 T-cell clones, and their specificity was evaluated using autologous DC transduced with LV-GFP and LV-s-HA-LAMP-1. Figure 4a shows that these T-cell clones (1, 2, 4, 9, 11, 13, 22, 27 and 28) recognized DC transduced with both LV-GFP and LV-s-HA-LAMP-1, whereas untransduced DC were not recognized, indicating that these T-cell clones were specific for vector-related antigen. To evaluate which component of lentiviral vectors is immunogenic, autologous DC loaded with FCS, human serum (HS) and transduced with LV-GFP or LV-s-HA-LAMP-1 were incubated with CD4 T-cell clones. Figure 4b shows that CD4 T-cell clones recognized DC loaded with FCS, but not HS, indicating that these CD4 T-cell clones were FCS specific. To identify the source of FCS that elicits this response, we transfected 293T cells with non-lentiviral control plasmid and concentrated 'empty lentiviruses' by ultracentrifugation. We found that these CD4 T cell-clones also recognized DC loaded with the pellet of the 'empty lentiviruses' (Figure 4c ). However, they did not recognize DC transduced with LV-GFP made in serum-free medium by Lipofectamine transfection (Figure 4c ). These results indicate that FCS is indeed derived from the vector preparation, and that when the lentiviruses were concentrated, the FCS protein accumulated in the pellet.
Next we determined HLA class II restriction of these T-cell clones. 293T cells stably expressing HLA-DR1 and DR4 were used as antigen-presenting cells and transduced with LV-GFP. Figure 4d shows that clones 2, 8 and 11 were HLA-DR1 restricted, clones 9, 14, 17 and 27 were HLA-DR4 restricted and clone 22 was both HLA-DR1 and -DR4 restricted ( Figure 4d ).
Solution to the problem with fetal calf serum immunogenicity
In order to find a solution to the FCS immunogenic problem in lentiviral production, we adapted 293T cells to grow in medium supplemented with HS and produced LV-HA and LV-GFP in this HS-containing medium. Human serum-adapted 293T cells do not adhere firmly to tissue culture plates or flasks, and are therefore difficult to maintain at an optimal condition during lentiviral production (H Guo et al., unpublished data). To produce high-titer LVs with no FCS immunogenicity, we produced high-titer LVs (B4 Â 10 7 transduction units (TU) ml -1 ) in 293T cells cultured with FCS and replaced FCS medium with serum-free medium 12 h after transfection. Figure 6a shows that LV-HA-NGFR produced under the serum-free conditions (two preps, SF1 and SF2) contained significantly reduced amounts of FCS. Sucrose (20%) or sucrose gradient purified (20/ 60%) LVs did not significantly reduce FCS compared with the unpurified LVs, and this method also led to a significant loss of viral particles (data not shown). T-cell assays further showed that serum-free, but not sucrosepurified LV-HA-NGFR, failed to sensitize DC for recognition by FCS-specific CD4 T-cell clones 9 and 22; however, they were recognized by an HA-specific clone, HA B16 (Figure 6b ). Flow cytometric analysis confirmed 
Discussion
To our knowledge, there has been no published report showing that human DC transduced with LVs that were prepared in FCS-cultured 293T cells stimulate FCSspecific, but not antigen-specific, CD4 T cells in vitro. This surprising finding is in great contrast with the several published reports showing that lentivirally transduced DC are capable of stimulating primary CD4 and CD8 T cells to a specific antigen. [13] [14] [15] [16] [17] [18] [19] Gruber et al.
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first reported that DC transduced with multiple deleted HIV-1 vectors exhibited normal phenotypes and functions and elicited an HIV-specific cytotoxic T-cell response in vitro. In this study, Grubber et al. produced VSV-G pseudotyped HIV-1 vectors in FCS-cultured 293T cells and used supernatants collected at 72 h after transfection to transduce DC at an MOI of 5. After five rounds of weekly restimulation of CD8 + T cells from HLA-A2.1 healthy donors with transduced DC, HIV-1-specific CTL were generated. Subsequently, several laboratories used DC transduced with supernatants or concentrated LVs produced in 293T cells to efficiently stimulate influenza, melanoma and HIV-specific CD8 and CD4 T-cell responses in vitro. [14] [15] [16] [17] [18] These results indicate the potential for application of LV-transduced DC in viral and cancer immunotherapy. 19 Here we used in vitro T-cell biological analysis and DC transduced with LVs as proof of principle to initially generate HA antigen-specific CD4 T cells from healthy donors and ultimately human minor histocompatibility antigen-specific CD4 T cells for epitope identification. We then established CD4 T-cell clones and found that these T-cell clones recognize FCS derived from the standard 293T cell lentivirus preparation; we noted that FCS might have been removed by ultracentrifugation during preparation. It seems that this is not the case, as these CD4 T-cell clones can recognize DC loaded with the pellet of empty vectors, but not with LV-GFP prepared in HScontaining medium or serum-free medium (Figures 4c  and 6b) .
Immune reactions to gene therapy products present significant obstacles to effective human gene therapy. For instance, immune destruction of gene-modified cells by an immune response against novel protein products of newly introduced genes has been reported. 21, 22 A strong immune response to components of the culture system has been observed in gene therapeutic trials. Reactions to FCS in immunodeficient patients who received multiple infusions of cultured white blood cells has been reported 
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earlier. [23] [24] [25] Development of IgE antibodies to FCS has been shown to correlate with a type I hypersensitivity reaction. High titers of precipitating antibody to FCS in the serum of a patient after third cell infusion were detected, although cells were extensively washed before being infused and no residual FCS was detectable in the final infusion medium. 24 Antibodies to vector particles in mouse serum after LV transduction of the brain have been reported. 26, 27 The common feature among these findings is that these products may give rise to a host immune response, which could lead to rapid clearance of virally transduced cells after infusion.
In conclusion, DC transduced with concentrated LVs can stimulate FCS-specific CD4 T-cell responses, emphasizing the importance of minimizing foreign proteins in lentiviral production. FCS contamination during LV production can be eliminated by using serum-free medium replacement after transfection, resulting in high-titer LVs with no detectable recognition of FCS antigen by T cells. These FCS-specific CD4 T-cell clones may be useful in testing clinical grade LVs for the presence of residual FCS contamination, as they are produced in FCS-cultured 293T cells and purified by size-exclusion chromatography. 4 
Materials and methods
Cell lines and culture medium
The 293T cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). 293IMDR1 cells are genetically modified 293 cells expressing HLA-DMA, HLA-DMB and invariant chain (Ii) in addition to DRa and DRb1*0101; 293IMDR4 cells express the same set of genes except DRb1*0401. (Figure 1 ). To enhance antigenspecific CD4 T-cell response, we constructed an MHC class II-targeting construct using an ER signal sequence from adenovirus E3/19K and human LAMP-1 to target HA into the MHC class II-processing pathway, 20 and was given the name LV-s-HA-LAMP-1. The signal and LAMP-1 sequences were verified by sequencing analysis (data not shown). LV-EF1a.NGFR vector was a gift of Dr Yan Cui (Louisiana State University Health Sciences Center, New Orleans, LA, USA). LV-HA-NGFR (pEHAmCNsin) vector was a self-inactivating HIV-1-derived vector with a bidirectional promoter-regulating HA and DNGFR expression. 29 To produce lentiviruses, 293T cells were plated at a density of 15 Â 10 6 per 15-cm-diameter culture dish and grown in DMEM medium (Invitrogen) supplemented with 10% FCS (Hyclone) for 24 h. The cells were cotransfected with 20 mg of vector plasmid, 15 mg of packaging plasmid pCMVDR8.91 and 5 mg of pMD.G plasmid using the DNA calcium phosphate co-precipitation method. 30 In some cases, LV-GFP or LV-NGFR was added at the amounts of 1/10 to the LV-HA or LV-s-HA-LAMP-1 for viral production, and GFP or NGFR was used as reporter genes to titer LVs. The transfection medium was replaced with fresh medium 16 h after . To produce serum-free lentiviruses, transfection was carried out in a similar way to that described above, except that the transfection medium was removed, the cells were washed with PBS and serum-free medium (HYQ -SFM4HEK293, HyClone) was added. Forty-eight and 96 h after replacing serum-free medium, viruscontaining supernatants were collected and concentrated by ultracentrifugation. Viral titers ranged from 2-7 Â 10 7 TU ml -1 .
Lentiviral purification
Hank's Balanced Salt Solution reconstituted lentiviral pellets produced in FCS medium were loaded onto 20% sucrose (Fisher Scientific, Pittsburg, PA, USA) or 20-60% sucrose gradient, and centrifuged at 50 000 g for 1.5 h at room temperature. 31 The viral interface layer of the 20-60% gradient purification was collected after initial centrifugation and centrifuged once more at 50 000 g for 2 h at 4 1C. Viral pellets were reconstituted in Hank's Balanced Salt Solution and frozen in aliquots at À80 1C.
SDS-polyacrylamide gel electrophoresis
Reconstituted viral pellets were denatured under reducing condition and electrophoresed through 10% SDS-polyacrylamide gel . Proteins were visualized by staining with Coomassie Blue.
Generation of dendritic cells
Peripheral blood mononuclear cells were isolated from HLA-DR4 + normal volunteers by Ficoll-Paque (GE Healthcare, Piscataway, NJ, USA) gradient centrifugation. Cells were seeded at 1 Â 10 7 cells per well in 3 ml serum-free AIM-V medium (Invitrogen) in a 6-well plate (Corning) and PBMC were incubated at 37 1C for 2 h to allow for cell adherence. After 2 h incubation, the nonadherent cells were removed and cryopreserved at À80 1C. The adherent monocytes were cultured in AIM-V medium supplemented with 100 ng ml -1 granulocyte-macrophage colony-stimulating factor (GM-CSF) and 10 ng ml -1 IL-4 (R&D Systems, Minneapolis, MN, USA) for 5 days.
Lentiviral transduction of immature dendritic cells and their maturation
Day 5 immature DC were seeded at 5 Â 10 5 cells per well in a 24-well plate and co-cultured with concentrated lentiviruses at a MOI of 25-50 in 1 ml AIM-V medium supplemented with GM-CSF and IL-4. Polybrene was added to the medium at a final concentration of 8 mg ml -1 . After 24 h incubation, cells were washed twice to remove lentiviruses, resuspended in AIM-V and then matured for 24-48 h using a cocktail of cytokines consisting of 20 ng ml -1 tumor necrosis factor-a, 10 ng ml -1 IL-1b, 10 ng ml -1 IL-6 (R&D Systems) and 1 mg ml -1 prostaglandin E2 (PGE2, Sigma). After transduction, cells were phenotypically characterized by staining for CD80, CD83, CD86 (BD Biosciences) and HLA-DR (L243, ATCC) to ensure expression of typical phenotype of mature DC.
Generation of HA-specific CD4
+ T-cell lines using dendritic cells transduced with HA lentiviruses Purified (498%) CD4 + T cells using the CD4 + T-Cell Isolation Kit (Miltenyi Biotec, Auburn, CA, USA) from healthy donors were stimulated with autologous, irradiated (40 Gy) DC transduced with LV-HA or LV-s-HA-LAMP-1 (MOI ¼ 50) at a ratio of T:DC of 5:1 in 24-well plates with human T-cell medium consisting of RPMI-1640 (Invitrogen), 10% HS, 10 mM HEPES, 2 mM L-glutamine, 50 U ml -1 penicillin and 50 mg ml -1 streptomycin. The cell lines were restimulated with autologous irradiated DCs transduced with LV-HA or LV-s-HA-LAMP-1 at 7 and 14 days after the initial stimulation, and the medium was supplemented with IL-2 (50 IU ml -1 , Chiron, Emeryville, CA, USA) after each restimulation. The antigen specificity of the LV-stimulated CD4 T cells was assessed on day 20 after stimulation using GM-CSF release assay by enzymelinked immunosorbent assay (R&D Systems). ) was added the following day. T-cell clones were expanded in 24-well plates or flasks. 32 
Measurement of antigen-specific responses
CD4
+ T cells (2 Â 10 5 per well) were cultured in duplicate with DC (1-5 Â 10 4 per well), which were transduced with LVs or pulsed (10-20 mg ml -1 37 1C for 2 h and washed away) with HA306-318 peptide (Sigma Genosys, the Woodlands, TX, USA) in 96-well culture plates. Culture supernatants were collected after 24 h for measuring GM-CSF production by enzyme-linked immunosorbent assay (R&D Systems).
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